Evaluation of the Effects of L-carnitine Supplementation on Patients with COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19.COVID-19, Virus identifiedU07.1
- Registration Number
- IRCT20200921048794N1
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Age 18 to 60 years
Positive PCR Test
Hospitalization
Existence of Corona Virus Symptoms According to the Instructions of the Ministry of Health
Mild to Moderate Disease Severity
Exclusion Criteria
Pregnancy
Breastfeeding
Severe Cardiovascular Disease
HIV Infection
History of Taking L-carnitine Supplementation in the Past Month
Requires Care in the ICU
Taking Anti-Inflammatory Drugs out of the Medication Regimen
Patients with High and Critical Disease Severity
Patient Dissatisfaction to Enter the Plan
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method